Every 10-Q that Fortive Corp (FTV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FTV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FTV filings page.
Fortive Corporation delivered higher profitability in the quarter ended July 3, 2026, with total sales of $1,096.8 million, up 7.9% year over year and core revenue up 6.7%. Net earnings from continuing operations were $157.3 million and diluted EPS from continuing operations was $0.51, compared with $0.33 a year earlier. Operating margin improved to 19.1% from 16.7%, supported by favorable pricing, volume growth, Fortive Business System productivity, lower restructuring, and tariff refunds, partially offset by higher employee costs and mix. The effective tax rate fell to 12.4%, mainly from jurisdictional mix and valuation allowance changes.
By segment, Intelligent Operating Solutions generated $758.2 million of sales with a 26.8% operating margin, while Advanced Healthcare Solutions produced $338.6 million of sales and an 11.3% margin. For the first half, operating cash flow was strong at $521.0 million. Fortive ended the period with long-term debt of $3,509.3 million and commercial paper of $1,076.6 million, after issuing $600 million of 4.75% 2031 notes and $500 million of 5.25% 2036 notes and using the proceeds to retire $900 million of 3.15% 2026 notes. The company repurchased 12.3 million shares for $700.3 million and paid $18.4 million in dividends. It also completed a bolt-on AHS acquisition for approximately $58 million, recording $52 million of goodwill and $20 million of intangibles, while continuing to manage post‑separation arrangements with Ralliant as a discontinued operation.
Fortive Corporation reported solid first-quarter 2026 growth from continuing operations. Sales rose to $1.07 billion from $993.1 million a year earlier, driven by 5.3% core revenue growth split between higher prices and volumes. Net earnings from continuing operations increased to $136.4 million from $112.6 million, and diluted EPS from continuing operations improved to $0.44 from $0.33. Prior-year results included $59.3 million of earnings from discontinued Precision Technologies operations, which no longer contribute.
The Intelligent Operating Solutions segment delivered $743.2 million of sales with a 25.1% operating margin, while Advanced Healthcare Solutions generated $326.2 million of sales and expanded its operating margin to 10.0%. Gross margin remained strong at 63.2%, with operating margin rising to 17.9% as Fortive leveraged pricing, productivity initiatives, and restructuring, partly offset by higher compensation and tariffs.
Operating cash flow from continuing operations was $220.4 million. The company ended the quarter with $356.1 million of cash and $3.49 billion of long-term debt, supported by $1.24 billion of commercial paper and an undrawn $2.0 billion revolving credit facility. Fortive repurchased 8.9 million shares for about $500 million, leaving 304.9 million shares outstanding as of late April 2026.
Fortive (FTV) filed its Q3 2025 10‑Q, highlighted by the completed spin-off of its Precision Technologies segment as Ralliant. Q3 sales were $1,027.1 million versus $1,003.7 million a year ago. Net earnings from continuing operations were $117.0 million, while discontinued operations posted a $62.0 million loss, resulting in net earnings of $55.0 million and diluted EPS of $0.16.
On June 28, shareholders received one Ralliant share for every three Fortive shares (record date June 16). Ralliant paid a $1.15 billion cash dividend to Fortive funded by new borrowings. Fortive used the cash to redeem €252 million of 3.7% euro notes due 2026 (about $302 million applied) and repay the Euro ($324 million) and Yen ($98 million) term loans. Long‑term debt carrying value was $3,306.3 million, including $755.0 million of commercial paper; the $2.0 billion revolver had no borrowings.
Fortive repurchased 20.8 million shares in Q3 at an average $47.98, reducing shares outstanding to 317.6 million at quarter‑end. Cash and equivalents were $430.8 million. By segment, Intelligent Operating Solutions delivered $698.8 million of Q3 sales and Advanced Healthcare Solutions $328.3 million.
Fortive’s Q2-25 results show modest top-line erosion and margin compression ahead of the Precision Technologies (PT) spin. Revenue slipped 2.2% YoY to $1.52 bn as softer product sales in PT (-5%) offset stable Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS). Gross margin eased 80 bp to 59.0%, while operating margin contracted 480 bp to 14.6% on $41 m separation costs and higher SG&A. Net earnings fell 14.6% to $166.6 m; diluted EPS dropped to $0.49 (vs $0.55).
Cash strengthened but leverage ticked up. Operating cash flow of $552.9 m (-2% YoY) plus lower capex lifted cash & equivalents to $1.83 bn from $813 m at FY-24. Total debt rose to $4.81 bn (vs $3.71 bn) with $1.15 bn of new Ralliant term-loans classified as current until the 28 Jun 25 spin. Current debt therefore jumped to $1.91 bn. Net debt/EBITDA remains manageable at ~1.6× (pro-forma).
Strategic actions. On 28 Jun 25 Fortive completed the tax-free distribution of PT as Ralliant, receiving a $1.15 bn dividend which management is using to redeem €252 m of 3.7% notes, repay euro/yen term loans and fund a special share-repurchase program announced 27 May 25. Beginning Q3-25, Ralliant will be reported as discontinued operations, simplifying Fortive to IOS and AHS.
Liquidity & outlook. Undrawn $2.0 bn revolver backs commercial paper ($395 m outstanding). FX-translation gains added $178 m to AOCI. Management continues a discrete restructuring (charges: $12 m YTD) to resize post-spin cost base. No forward guidance was provided in the filing.